Serum Alpha and Beta‐CGRP Levels in Chronic Migraine Patients Before and After Monoclonal Antibodies Against CGRP or its Receptor
Annals of Neurology · 2023-08 · 94 (2) · 285-294
DOI: 10.1002/ana.26658 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Neurology, online erschienen am 21.04.2023. Verfasst von Gabriel Gárate und 6 weiteren Autor:innen. Beteiligte Einrichtung: Service of Neurology of the University Hospital Marqués de Valdecilla, Santander, Spain. Hauptthemen laut MEDLINE: Calcitonin Gene-Related Peptide, Migraine Disorders. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Eli Lilly and Company, Instituto de Investigación Marqués de Valdecilla, Instituto de Salud Carlos III.
Abstract (Originalsprache)
Objective
The objective of this study was to analyze the evolution of alpha and beta‐CGRP circulating levels throughout CGRP monoclonal antibodies (mAbs) treatment in patients with chronic migraine (CM).
Methods
We recruited patients with CM beginning mAbs along with sex and age paired healthy controls (HCs). Blood was extracted before, 2 weeks (M0.5) and 3 months (M3) after the first dose of mAbs, always in free‐migraine periods, and once for HCs. Alpha and beta‐CGRP serum levels were measured using enzyme‐linked immunosorbent assays (ELISAs) specific for each isoform.
Results
Baseline alpha‐CGRP levels were significantly elevated in 103 patients with CM (median = 50.3, 95% confidence interval [CI] = 40.5–57.0 pg/ml) compared to 78 HCs (median = 37.5, 95% CI = 33.9–45.0 pg/ml; 95% CI of differences = 2.85–17.08 pg/ml) and significantly decreased (n = 96) over the course of mAb treatment (M0.5: median = 40.4, 95% CI = 35.6–48.2 pg/ml; and M3: median = 40.9, 95% CI = 36.3–45.9 pg/ml). Absolute decrease of alpha‐CGRP throughout the treatment positively correlated with the decrease in MMDs. Negative modulation of alpha‐CGRP significantly associated with positive scores at the Patient Global Impression of Change scale and with analgesic overuse reversal. Beta‐CGRP did not differ at baseline between patients with CM (median = 4.2, 95% CI = 3.0–4.8 pg/ml) and HCs (median = 4.4, 95% CI = 3.4–5.6 pg/ml; −1.09 to 0.60) nor was modulated by mAb treatment (n = 96; M0.5: median = 4.5, 95% CI = 3.5–5.2 pg/ml; and M3: median = 4.6, 95% CI = 3.7–5.2 pg/ml).
Interpretation
Treatment with mAbs, regardless of its target, is able to progressively normalize basally increased alpha‐CGRP levels in CM and this effect correlates with efficacy measures, which supports a role of this neuropeptide as the first CM biomarker. ANN NEUROL 2023;94:285–294
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Service of Neurology of the University Hospital Marqués de Valdecilla, Santander, Spain.
- Instituto de Investigación Valdecilla, IDIVAL, Santander, Spain.
- Universidad de Cantabria, Santander, Spain.
- Service of Gastroenterology of the University Hospital Marqués de Valdecilla, Santander, Spain.
ORCID-Profile: Julio Pascual
Förderung
- Eli Lilly and Company
- Instituto de Investigación Marqués de Valdecilla
- Instituto de Salud Carlos III
Zitieren
APA
Gárate, G., González-Quintanilla, V., González, A., Pascual, M., Pérez-Pereda, S., Madera, J., & Pascual, J. (2023). Serum Alpha and Beta‐CGRP Levels in Chronic Migraine Patients Before and After Monoclonal Antibodies Against CGRP or its Receptor. Annals of Neurology, 94(2), 285-294. https://doi.org/10.1002/ana.26658
Vancouver
Gárate G, González-Quintanilla V, González A, Pascual M, Pérez-Pereda S, Madera J, et al. Serum Alpha and Beta‐CGRP Levels in Chronic Migraine Patients Before and After Monoclonal Antibodies Against CGRP or its Receptor. Annals of Neurology. 2023;94(2):285-294. doi:10.1002/ana.26658
BibTeX
@article{Grate2023,
author = {Gárate, Gabriel and González-Quintanilla, Vicente and González, Andrea and Pascual, Marta and Pérez-Pereda, Sara and Madera, Jorge and Pascual, Julio},
title = {Serum Alpha and Beta‐CGRP Levels in Chronic Migraine Patients Before and After Monoclonal Antibodies Against CGRP or its Receptor},
journal = {Annals of Neurology},
year = {2023},
volume = {94},
number = {2},
pages = {285--294},
doi = {10.1002/ana.26658}
}
EUVIMED